Itopride Dosing and Administration
Itopride should be taken as 50 mg tablets three times daily, administered 30 minutes before meals, for a treatment duration of 4-8 weeks. 1, 2
Standard Dosing Regimen
- Take 50 mg orally three times daily before meals 1, 2, 3
- Administer approximately 30 minutes before breakfast, lunch, and dinner to optimize prokinetic effects 2
- Standard treatment duration is 4-8 weeks, with symptom assessment at weeks 4 and 8 1
- A 2-week follow-up period after treatment completion is recommended to assess sustained symptom relief 2
Extended-Release Formulation Alternative
- Itopride SR (sustained-release) can be given as 150 mg once daily for improved compliance 4, 5
- The once-daily ER formulation provides bioavailability comparable to 50 mg IR three times daily 5
- Food delays absorption of the ER formulation but does not significantly affect overall bioavailability 5
- The ER formulation may be preferred for patients with adherence concerns or those requiring simplified dosing 4
Treatment Response Timeline
- Initial symptom improvement typically begins within 1 week, with response rates of 33-36% 2
- By week 2, response rates increase to 52-57% 2
- Optimal therapeutic effect is achieved by week 4, with response rates of 72-75% 2
- Continued improvement may be observed through week 8, with up to 86% of patients achieving therapeutic effect 1
Renal and Hepatic Considerations
No dose adjustment is required for patients with renal or hepatic impairment, as itopride is well-tolerated across various patient populations 1, 2, 3
- Baseline renal and liver function tests should be obtained before initiating therapy 3
- Monitoring of these parameters during treatment is recommended, particularly in patients with pre-existing dysfunction 3
- The drug has demonstrated safety in patients with normal organ function without causing biochemical abnormalities 3
Safety Monitoring
- Baseline ECG should be performed to assess QT interval 3
- Itopride does not cause QT prolongation, unlike some other prokinetic agents 3
- Adverse events are uncommon (1.5-3% incidence) and typically mild 1, 2
- Most common adverse effects include mild gastrointestinal symptoms and rare cardiac arrhythmias (atrial extrasystole) that resolve spontaneously 1
Clinical Pitfalls to Avoid
- Do not administer itopride after meals, as pre-meal timing is essential for optimal prokinetic activity 2
- Avoid premature discontinuation before 4 weeks, as maximal therapeutic benefit requires adequate treatment duration 2
- Do not confuse itopride with other prokinetics (metoclopramide, domperidone) that have different safety profiles and dosing schedules 2, 3
- The immediate-release formulation requires strict three-times-daily dosing; if compliance is an issue, switch to the ER formulation rather than reducing dosing frequency 5
Special Populations
- Diabetic gastroparesis patients: The same dosing regimen applies, with significant symptom improvement observed across all severity categories 4
- Elderly patients: No specific dose adjustment required, though baseline assessment of organ function is prudent 1
- Patients previously on other prokinetics: Direct substitution with itopride at standard doses is appropriate without washout period 3